LOGIN  |  REGISTER
C4 Therapeutics
Recursion

908 Devices to Participate in the William Blair 43rd Annual Growth Stock Conference

May 23, 2023 | Last Trade: US$2.39 0.01 0.42

BOSTON / May 23, 2023 / Business Wire / 908 Devices Inc., (Nasdaq: MASS) a pioneer of handheld and desktop devices for chemical and biochemical analysis, today announced it will participate in the upcoming William Blair 43rd Annual Growth Stock Conference.

908 Devices’ management is scheduled to present on Wednesday, June 7 at 1:20 p.m. Central Time / 2:20 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company website at: www.908devices.com.

About 908 Devices

908 Devices is revolutionizing chemical and biochemical analysis with its simple handheld and desktop devices, addressing critical-to-life applications. The Company’s devices are used at the point-of-need to interrogate unknown and invisible materials and provide quick, actionable answers to directly address some of the most critical problems in life sciences research, bioprocessing, pharma/biopharma, forensics and adjacent markets. The Company is headquartered in the heart of Boston, where it designs and manufactures innovative products that bring together the power of mass spectrometry, microfluidic sampling and separations, software automation, and machine learning.

Recursion

Stock Quote

Featured Stock

Recursion

Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....

CLICK TO LEARN MORE

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB